SandRidge Mississippian Stock (OTC: SDTTU)

Latest news for SandRidge Mississippian (OTC:SDTTU) Stock

SandRidge Mississippian Trust I is a statutory trust which holds royalty interests in specified oil and natural gas properties located in the Mississippian formation in Alfalfa, Garfield, Grant, and Woods counties in Oklahoma. The royalty interests entitle the Trust to receive most of the proceeds from the sale of oil, natural gas, and natural gas liquids.

SANDRIDGE MISSISSIPPN TR by SandRidge Mississippian Trust I

SandRidge Mississippian Trust I

Over the past 24 hours, Bittensor's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TAO</a>) price rose 9.56% to $408.24. This continues its positive trend over the past week where it has experienced a 29.0% gain, moving from $312.66 to its current price. As it stands right now, the coin's all-time high is $757.60. 
The chart below compares the price movement and volatility for Bittensor over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726859021_0.png" alt="price_chart" />
The trading volume for the coin has risen 126.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.69%. This brings the circulating supply to 7.38 million, which makes up an estimated 35.15% of its max supply of 21.00 million. According to our data, the current market cap ranking for TAO is #34 at $3.01 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726859021_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

Trading Ideas

$TAO

Cryptocurrency Bittensor Rises More Than 9% In 24 hours

Kaspa's (CRYPTO:KAS) price has decreased 3.42% over the past 24 hours to $0.17, continuing its downward trend over the past week of -1.0%, moving from $0.17 to its current price. 
The chart below compares the price movement and volatility for Kaspa over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726858954_0.png" alt="price_chart" />
Kaspa's trading volume has climbed 44.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.52%. This brings the circulating supply to 24.75 billion, which makes up an estimated 86.21% of its max supply of 28.70 billion. According to our data, the current market cap ranking for KAS is #27 at $4.18 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726858954_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cryptocurrency Kaspa Falls More Than 3% In 24 hours

Over the past 24 hours, Aptos's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APT</a>) price has risen 6.02% to $7.26. This continues its positive trend over the past week where it has experienced a 14.0% gain, moving from $6.29 to its current price. As it stands right now, the coin's all-time high is $19.92. 
The chart below compares the price movement and volatility for Aptos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726858945_0.png" alt="price_chart" />
Aptos's trading volume has climbed 200.0% over the past week along with the circulating supply of the coin, which has increased 0.23%. This brings the circulating supply to 500.28 million. According to our data, the current market cap ranking for APT is #31 at $3.63 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726858945_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$APT

Cryptocurrency Aptos Up More Than 6% In 24 hours

A Georgia pharmacy has started selling low-THC medical marijuana to registered patients statewide, despite opposition from the <a href="https://www.benzinga.com/topic/drug-enforcement-administration">Drug Enforcement Administration (DEA).</a>
Vic Johnson, who owns the Living Well Pharmacy in Augusta, <a href="https://www.ajc.com/news/health-news/independent-georgia-pharmacy-is-dispensing-medical-marijuana-defying-dea-warning/ZML4KLIPQ5HQDLZ4GIRU27MXLI/">told</a> the Journal-Constitution that selling medical cannabis in pharmacies is "a new frontier."
Why? "I really think pharmacies are an ideal outlet for dispensing medical cannabis because if you come to my pharmacy already, we can talk about what medications you already are taking."
The Georgia Board of Pharmacy started accepting applications from nearly 120 pharmacies to provide medical marijuana products in October, making it the first state in the nation to allow the sale of low-dose cannabis at independent drug stores. The move came four years after the Georgia legislature legalized low-THC medical marijuana in 2019.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20133836/ccc-oct-24-banner__1_-33.gif" alt="" class="wp-image-558952" /></a></figure>
Botanical Sciences LLC and Trulieve Cannabis Corp. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTCQX">TCNNF</a>), which were the first cannabis businesses to launch medical cannabis sales statewide in 2023, were given the green light to supply pharmacies with products.
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">DEA Is Against It</h3>
The DEA sent warning letters to pharmacies involved in the state&#8217;s medical marijuana program shortly after, cautioning against dispensing THC. Even though the DEA's move prompted concerns among industry stakeholders about potential obstacles to the expansion of medical marijuana access for patients statewide, the Georgia Access to Medical Cannabis Commission (GMCC) maintained its stance.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/23/12/36246587/dea-vs-georgia-tensions-rise-over-medical-cannabis-access-as-state-regulators-consider-legal-act">DEA vs. Georgia: Tensions Rise Over Medical Cannabis Access As State Regulators Consider Legal Action</a>
"I want patients to know that we are well on our way to fully implement the Hope Act [Harnessing Opportunities by Pursuing Expungement Act]," GMCC chair Sid Johnson said. "We will continue to pursue our mission of ensuring access to medical cannabis for all patients across Georgia."
Johnson's pharmacy was earlier approved by the Georgia Board of Pharmacy to dispense low-THC oil to Richmond County's registered patients. He said his pharmacy got the green light to sell medical cannabis gummies, tinctures, cremes or capsules that contain 5% THC or marijuana compound in late August.
"I think our customers feel more comfortable buying this product through a pharmacy where records are kept, and we know their medical history," Johnson <a href="https://augustabusinessdaily.com/local-pharmacy-creating-a-buzz-with-thc-sales/">told</a> Augusta Business Daily. "The other benefit is that the purchases for these products are kept separate from other prescriptions we fill."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/10/35491477/cannabis-milestone-over-the-counter-medical-marijuana-launches-in-georgia-pharmacies">Cannabis Milestone: Over-The-Counter Medical Marijuana Launches In Georgia Pharmacies</a></li>
</ul>
Photo: Africa Studio/Shutterstock.com

Cannabis

Government

News

Regulations

Politics

TCNNF

TRUL

Buying Cannabis At Pharmacy Feels 'More Comfortable,' Says Owner Of Georgia Drugstore Launching Low-THC MMJ Sales

Ratings for BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated BOK Financial and provided 12-month price targets. The average target is $109.11, accompanied by a high estimate of $123.00 and a low estimate of $94.00. Surpassing the previous average price target of $99.44, the current average has increased by 9.72%.
<img src="https://www.benzinga.com/files/images/story/2024/1726858922_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive BOK Financial. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$123.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Wood Lay</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$114.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Gary Tenner</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$111.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$112.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Matt Olney</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$115.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$99.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$94.00</td>
<td>$97.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BOK Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BOK Financial compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of BOK Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into BOK Financial's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BOKF/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on BOK Financial analyst ratings.</a>
<h2>Unveiling the Story Behind BOK Financial</h2>
BOK Financial Corp is the largest financial institution in Oklahoma and it provides a comprehensive range of nationally competitive financial products and services. Its operating segments consist of commercial banking, consumer banking, and wealth management. The company has various products and services including cash management services, loans and deposits, fiduciary and insurance services, mortgage banking and brokerage and trading services. It generates maximum revenue from the commercial banking segment. Its commercial banking segment includes lending, treasury and cash management services, and customer risk management products to small businesses, middle market, and larger commercial customers.
<h3>BOK Financial: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, BOK Financial showcased positive performance, achieving a revenue growth rate of 4.62% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: BOK Financial's net margin excels beyond industry benchmarks, reaching 29.63%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): BOK Financial's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.13%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): BOK Financial's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.32% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 1.27, BOK Financial faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

BOKF

Forecasting The Future: 9 Analyst Projections For BOK Financial

In the preceding three months, 10 analysts have released ratings for Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Acadia Healthcare Co, presenting an average target of $88.2, a high estimate of $94.00, and a low estimate of $75.00. Highlighting a 0.11% decrease, the current average has fallen from the previous average price target of $88.30. 
<img src="https://www.benzinga.com/files/images/story/2024/1726858904_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Acadia Healthcare Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Pito Chickering</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Acadia Healthcare Co. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Acadia Healthcare Co compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Acadia Healthcare Co's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Acadia Healthcare Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ACHC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Acadia Healthcare Co analyst ratings.</a>
<h2>All You Need to Know About Acadia Healthcare Co</h2>
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities in the United States, United Kingdom, and Puerto Rico. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The U.S. facilities receive the major proportion of payments from Medicaid, with the second-largest proportion from commercial payors. In the United Kingdom, the majority of Acadia's revenue comes from its healthcare facilities, and virtually all of the payment received is from the National Health Service.
<h3>Acadia Healthcare Co: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Acadia Healthcare Co's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.85%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Acadia Healthcare Co's ROE excels beyond industry benchmarks, reaching 2.7%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Acadia Healthcare Co's ROA excels beyond industry benchmarks, reaching 1.4%. This signifies efficient management of assets and strong financial health.
Debt Management: Acadia Healthcare Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.67.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHC

What Analysts Are Saying About Acadia Healthcare Co Stock

Ratings for Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Pinnacle Finl Partners, presenting an average target of $101.75, a high estimate of $113.00, and a low estimate of $87.00. Observing a 6.97% increase, the current average has risen from the previous average price target of $95.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1726858885_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Pinnacle Finl Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Steven Shaw</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$97.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$108.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pinnacle Finl Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Pinnacle Finl Partners's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pinnacle Finl Partners's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Pinnacle Finl Partners analyst ratings.</a>
<h2>Discovering Pinnacle Finl Partners: A Closer Look</h2>
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. Pinnacle operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
<h3>A Deep Dive into Pinnacle Finl Partners's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3 months period, Pinnacle Finl Partners faced challenges, resulting in a decline of approximately -9.98% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 15.55%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Pinnacle Finl Partners's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.83%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.1%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.43, Pinnacle Finl Partners adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNFP

Key Takeaways From Pinnacle Finl Partners Analyst Ratings

Artificial Superintelligence Alliance's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/fet/usd">FET</a>) price has increased 4.98% over the past 24 hours to $1.6. Over the past week, FET has experienced an uptick of over 14.0%, moving from $1.39 to its current price. As it stands right now, the coin's all-time high is $3.45. 
The chart below compares the price movement and volatility for Artificial Superintelligence Alliance over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726858875_0.png" alt="price_chart" />
Artificial Superintelligence Alliance's trading volume has climbed 12.0% over the past week along with the circulating supply of the coin, which has increased 0.56%. This brings the circulating supply to 2.52 billion, which makes up an estimated 95.84% of its max supply of 2.63 billion. According to our data, the current market cap ranking for FET is #28 at $4.04 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726858875_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$FET

Cryptocurrency Artificial Superintelligence Alliance Up More Than 4% In 24 hours

Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.86, a high estimate of $37.00, and a low estimate of $18.00. This current average represents a 19.15% decrease from the previous average price target of $34.46. 
<img src="https://www.benzinga.com/files/images/story/2024/1726858866_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Progyny among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$18.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$21.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$31.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$24.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$25.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Constantine Davides</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$36.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Progyny. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Progyny compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Progyny's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Progyny's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PGNY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Progyny analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Progyny Better</h2>
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
<h3>Progyny's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Progyny's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 8.85%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Progyny's net margin excels beyond industry benchmarks, reaching 5.42%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Progyny's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.21%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Progyny's ROA excels beyond industry benchmarks, reaching 2.21%. This signifies efficient management of assets and strong financial health.
Debt Management: Progyny's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PGNY

Beyond The Numbers: 14 Analysts Discuss Progyny Stock

In the preceding three months, 11 analysts have released ratings for Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.0, a high estimate of $74.00, and a low estimate of $55.00. This current average has decreased by 3.9% from the previous average price target of $66.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1726858837_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Terex is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$63.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>David Raso</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$59.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Mircea Dobre</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Stephen Volkmann</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$59.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$60.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Terex. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Terex compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Terex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Terex analyst ratings.</a>
<h2>About Terex</h2>
Terex is a top manufacturer of aerial work platforms, materials processing equipment, and specialty equipment, such as material handlers, cranes, and concrete mixer trucks. Its current composition is a result of numerous acquisitions over several decades and a recent shift to focus on its two core segments after divesting a handful of underperforming businesses. Terex's remaining segments see heavy demand in nonresidential construction as well as in maintenance, manufacturing, energy, and materials management.
<h3>A Deep Dive into Terex's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Terex's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -1.53% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 10.18%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Terex's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 7.91%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.73%, the company showcases effective utilization of assets.
Debt Management: Terex's debt-to-equity ratio is below the industry average. With a ratio of 0.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Terex Stock: Analyst Perspectives (11 Ratings)

Throughout the last three months, 5 analysts have evaluated Glacier Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBCI#NYSE">GBCI</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $42.0, a high estimate of $50.00, and a low estimate of $38.00. This upward trend is apparent, with the current average reflecting a 4.48% increase from the previous average price target of $40.20.
<img src="https://www.benzinga.com/files/images/story/2024/1726858823_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Glacier Bancorp is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Matthew Clark</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$46.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Glacier Bancorp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glacier Bancorp compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Glacier Bancorp's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Glacier Bancorp's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GBCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Glacier Bancorp analyst ratings.</a>
<h2>All You Need to Know About Glacier Bancorp</h2>
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's wide range of products and services include deposit, loans, and mortgage origination services, among others. The bank primarily serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier's strategy emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
<h3>Unraveling the Financial Story of Glacier Bancorp</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Glacier Bancorp's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -1.41% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 23.08%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Glacier Bancorp's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.43%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Glacier Bancorp's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.16%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.82, caution is advised due to increased financial risk.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GBCI

Analyst Expectations For Glacier Bancorp's Future

Over the past 24 hours, Sui's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">SUI</a>) price has risen 11.21% to $1.49. This continues its positive trend over the past week where it has experienced a 44.0% gain, moving from $1.03 to its current price. As it stands right now, the coin's all-time high is $2.17. 
The chart below compares the price movement and volatility for Sui over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1726858805_0.png" alt="price_chart" />
The trading volume for the coin has risen 192.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.12%. This brings the circulating supply to 2.68 billion, which makes up an estimated 26.8% of its max supply of 10.00 billion. According to our data, the current market cap ranking for SUI is #29 at $3.99 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1726858806_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$SUI

Cryptocurrency Sui Up More Than 11% In 24 hours

Fifth Third Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fitb#NASDAQ">FITB</a>) shares touched a 52-week high of $43.85 on Thursday following the Federal Reserve&#39;s announcement of a 50-basis points interest rate cut.
The FITB stock closed slightly lower at $43.64, gaining nearly 18% over the past six months. It has outperformed its industry, the S&amp;P 500 Index and its close peers like Comerica Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cma#NYSE">CMA</a>) and Bank of America Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bac#NYSE">BAC</a>) in the same time frame.
<h3>Six-Month Price Performance</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/f3/78671.jpg?v=1259988145" />
Image Source: Zacks Investment Research
<h2>Key Drivers Behind FITB Stock&#39;s New 52-Week High</h2>
A major factor for this upward movement of FITB stock can be attributed to the Federal Reserve&#39;s aggressive start to monetary policy easing.
On Wednesday, the central bank signaled two additional rate cuts this year to support the economy. Fed officials further indicated plans for four more cuts in 2025 and two in 2026.
The interest rate cut is a positive development for banks, including Fifth Third, CMA and BAC, which have been struggling with rising funding cost pressures. While higher rates have led to a significant jump in banks&#39; net interest income (NII) the same led to increased funding costs, which squeezed margins.
FITB&#39;s NII has witnessed a three-year (2020-2023) compound annual growth rate of 6.8%. However, the company&#39;s NII declined in the first half of 2024 due to higher funding costs.
So now that the Fed has cut the rates, funding costs will gradually stabilize and eventually start declining, thus supporting FITB&#39;s NII.
<h2>Other Factors Supporting FITB&#39;s Performance</h2>
Raised Guidance: At the Barclays Global Financial Services Conference, FITB raised its third-quarter 2024 outlook. The bank stated that total revenues are now expected to rise 2-3% sequentially in the third quarter from its baseline of $2.2 billion compared with the previous guidance of a 1-2% increase. Also, management updated its non-interest income, now expecting a 3-4% increase from its baseline of $717 million, up from the earlier projection of a 1-2% rise.
Strategic Collaborations: The company has been expanding its embedded payments platform on the back of strategic partnerships, positioning itself for substantial growth in the commercial payments space. Fifth Third&#39;s embedded payments platform, Newline, entered into a collaborative agreement with Trustly in September. This collaboration aims to develop its pay-by-bank arrangements and payments made through the Automated Clearing House&nbsp;and Real Time Payments networks.
In July, the bank announced a collaborative agreement between its embedded payments arm, Newline, and Stripe, a financial infrastructure platform, to expand embedded financial services offerings.
In May 2024, in collaboration with Bottomline, Fifth Third launched Enhanced Payables &mdash; a new payment platform powered by the latter&#39;s business payments network, Paymode-X. This partnership offers customers access to a wide range of payment options, including invoice automation, virtual card payments, premium ACH payments, standard ACH payments, check payments and business-to-consumer payments.
Through such strategic collaborations, the bank anticipates commercial payments to be a $1 billion business in the next five years. This will eventually boost the company&#39;s non-interest income growth over time.
Balance Sheet: The bank has a strong liquidity position. As of June 30, 2024, the company had a total debt (long-term debt and other short-term borrowings) of $19.7 billion and total liquidity (cash and due from banks and other short-term investments) of $23.9 billion. The company&#39;s senior debt enjoyed investment-grade credit ratings of BBB+, A- and Baa1 from Standard &amp; Poor&#39;s, Fitch and Moody&#39;s, respectively. This will likely enable the company to access the debt market at favorable rates.
Impressive Capital Distribution: The company is expected to keep enhancing shareholder value through efficient capital distribution.&nbsp; This month, the company announced a 5.7% rise in quarterly dividend to 37 cents per share. It has increased its dividend five times in the last five years. At present, the company has a dividend payout ratio of 40% with an annualized dividend growth rate of 8.55%.
Similarly, BAC hiked quarterly dividends by 8.3% in July to 26 cents, while CMA has kept its dividend payouts steady at 71 cents per share since February 2023.&nbsp;
In addition to dividends, the company has an impressive share repurchase plan. FITB repurchased 3.5 million of its outstanding common shares in the first half of 2024 as part of the 100-million-share repurchase plan announced on June 18, 2019. As of June 30, 2024, 28.6 million shares remain available under the authorization. Going forward, the company expects to repurchase $200 million worth of shares for each remaining quarter of 2024. Such efforts will enhance shareholder value in the long term.
<h2>Few Concerns Prevail for FITB</h2>
Mounting Expenses: Fifth Third&#39;s non-interest expense saw a five-year CAGR of 2.8%, ending 2023. In the first half of 2024, the non-interest expenses remained flat compared with the same period of last year. Higher compensation and benefits expenses, as well as initiatives, such as branch expansion and digitization, will keep the company&#39;s expense base under pressure in the short term.
Limited Loan Portfolio Diversification: The company&#39;s loan portfolio comprises majorly of commercial loans (61.6% of total portfolio loans and leases as of June 30, 2024). The current rapidly changing macroeconomic backdrop may put some strain on commercial lending. Moreover, in case of any economic downturn, the asset quality of these credit categories might deteriorate. Thus, the lack of loan portfolio diversification is likely to hurt the company&#39;s financials if the economic situation worsens.
<h2>Final Words on FITB</h2>
FITB&#39;s inorganic expansion efforts and a robust balance sheet position, along with the Fed&#39;s recent rate cut, are set to support FITB&#39;s financials in the upcoming period.
<h3>Sales Estimate</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ff/78672.jpg?v=1445542711" />
Image Source: Zacks Investment Research
<h3>EPS Estimate</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/dd/78673.jpg?v=1818770512" />
Image Source: Zacks Investment Research
<h2>Unlocking Valuation</h2>
FITB stock appears expensive relative to the industry. The company is currently trading at the 12-month trailing price-to-earnings (P/E) F12M ratio of 12.49%, above the industry&#39;s 11.59%.
<h3>P/E F12M</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/4f/78674.jpg?v=758532752" />
Image Source: Zacks Investment Research
Though the rising expense and lack of diversification in its loan portfolio remain near-term concerns, FITB&#39;s long-term prospects remain bright.
Considering its expensive valuation, prospective investors can keep this Zacks Rank #3 (Hold) stock on their radar and can wait for a better entry point.
<a href="https://www.zacks.com/stock/news/2339412/fitb-stock-hits-52-week-high-on-fed-rate-cut-is-it-worth-retaining?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2339412">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Mid Cap

Guidance

Dividends

FITB

FITB Stock Hits 52-Week High on Fed Rate Cut: Is It Worth Retaining?

Jesus Christ and his apostles could have used a cannabis-based anointing oil to help heal people with disabling diseases. A study exploring biblical texts has sparked a provocative discussion about the potential use of <a href="https://www.benzinga.com/topic/cannabis-news">cannabis</a> in ancient religious practices, specifically those associated with Jesus and his disciples. This research indicates that cannabis was likely a key ingredient in the anointing oils used during biblical times, supporting claims that Jesus may have utilized the plant for its medicinal properties.
<h3 class="wp-block-heading">Cannabis In Biblical Anointing Oils</h3>
According to Chris Bennett, <a href="https://archive.hightimes.com/article/2003/2/1/was-jesus-a-stoner">writing</a> for High Times, the substance known as kaneh-bosem, referenced in scripture, is now believed to be cannabis extract. Bennett cites various scholars who support this claim, suggesting that the oils used for anointing during Jesus&#8217; time contained this potent substance. "There can be little doubt about a role for cannabis in Judaic religion," Carl Ruck, a professor of classical mythology at Boston University, told The Guardian. Ruck elaborated: "Obviously the easy availability and long-established tradition of cannabis in early Judaism would inevitably have included it in the [Christian] mixtures."
Bennet recovered the research of Polish anthropologist <a href="https://findingaids.library.nyu.edu/archives/rism_rg_2/">Sula Benet</a>, who in 1936 discovered the translation error in the Old Testament, and then demonstrated in her essays "Tracing One Word Through Different Languages" (1936) and "<a href="https://www.xn--4dbcyzi5a.com/wp-content/PDF/EARLY-DIFFUSION-AND-FOLK-USES-OF-HEMP-SULA-BENET.pdf">Early Diffusions and Folk Uses of Hemp</a>" (1975), that the Hebrew terms "kaneh" and "kaneh-bosm" identified cannabis.
<h3 class="wp-block-heading">Healing Practices And Miraculous Effects</h3>
The research posits that the anointing oils not only played a ceremonial role but also served practical healing purposes. Bennett argued that those anointed with these oils were "literally drenched in this potent mixture." While many contemporary cannabis users prefer smoking or <a href="https://www.benzinga.com/topic/cannabis-edibles">ingesting</a> the plant, the ancient method of oil infusion allowed for absorption through the skin, potentially enhancing its <a href="https://www.benzinga.com/topic/medical-cannabis">therapeutic effects.</a>
Bennett drew connections between these practices and the healing miracles attributed to Jesus in the Gospels, particularly those involving skin and eye diseases. "If cannabis was one of the main ingredients of the ancient anointing oil, and receiving this oil is what made Jesus the Christ and his followers Christians, then persecuting those who use cannabis could be considered anti-Christ," he concluded.
<h3 class="wp-block-heading">Implications For Modern Perspectives On Cannabis</h3>
This perspective invites a reevaluation of how cannabis is viewed in both historical and contemporary contexts. As public opinion shifts toward more favorable views on cannabis, the implications of these findings could influence discussions about its place in religious and therapeutic practices today.
With ongoing debates about <a href="https://www.benzinga.com/topic/cannabis-legalization">cannabis legalization</a> and its medicinal benefits, the intersection of ancient traditions and modern science may help reshape conversations surrounding this historically significant plant.
Cover image made with AI

Psychedelics

Was Cannabis The Secret To Jesus' Healing Miracles? Study Uncovers Ancient Remedies

The announcement that Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) is bringing in Elliot Hill as the new CEO could be a positive change given his experience and company tenure, but it raises questions about the company&#8217;s strategy for a turnaround and plans to return to revenue growth.
The Nike Analysts: 
<ul>
<li>Piper Sandler analyst Anna Andreeva maintained a Neutral rating with a $80 price target.</li>
<li>KeyBanc analyst Ashley Owens maintained a Sector Weight rating with no price target.</li>
<li>Stifel analyst Jim Duffy maintained a Hold rating with a $79 price target.</li>
<li>BMO analyst Simeon Siegel reiterated an Outperform rating with a $92 price target.</li>
<li>Truist analyst Joseph Cirello maintained a Hold rating and raised the price target from $81 to $85.</li>
<li>RBC Capital analyst Piral Dadhania maintained a Sector Perform rating with a $75 price target.</li>
<li>JPMorgan analyst Matthew Boss maintained a Neutral rating with an $83 price target.</li>
</ul>
Piper Sandler on NKE: Nike's announcement is a positive for the stock, Andreeva said in a new investor note.
"This removes an overhang in leadership and creates a potentially interesting setup with the Investor Day in November," Andreeva said.
The analyst said that the announcement came sooner than expected, adding that a CEO with deep company experience could positively impact the company culture.
While the news is positive for the stock, Andreeva said Nike could stay "range-bound" until more color is provided on the company's new strategy.
KeyBanc on NKE: With a combined 32 years of experience in various roles at Nike, Hill could play a key role in driving growth at the company, Owens said.
"We view Hill's longstanding connection with the company and expertise within the marketing scope as encouraging, as NKE examines reinvigorating brand storytelling," Owens said.
Stifel on NKE: Bringing back a long-time Nike insider is viewed as a positive by Duffy.
"Recent underperformance is a direct result of losing focus on what has made Nike great for so many years," Duffy said. "Under Mr. Hill's leadership, we hope to see a revitalization of the Nike culture and a renaissance in innovation and design."
The analyst warns that changing CEOs can reset financial forecasts, trigger periods of product revitalization, and potentially lead to additional management changes.
Duffy added that timing the change ahead of Nike's November Investor Day is "purposefully" planned and could offer a clearer view of the company&#8217;s future direction.
BMO Capital on NKE: The hiring of Hill could bring an immediate morale boost to Nike thanks to being well-liked by employees and retail partners, Siegel said in a new investor note.
The analyst said that CEO changes often take time to yield results, but Hill could help Nike regain success in areas such as product development and marketing.
"A new CEO changes the dynamic for the upcoming analyst day and we believe breathes new life and hope into a semi-abandoned blue-chip company in an environment where investors are looking for exactly that," Siegel said.
Read Also: <a href="https://www.benzinga.com/news/24/09/40957353/nikes-new-ceo-elliott-hill-to-focus-on-repairing-retailer-relations">Nike&#8217;s New CEO Elliott Hill To Focus On Repairing Retailer Relations</a>
Truist on NKE: Cirello cautions that the near-term upside for Nike could be limited after shares jumped on news of Hill's hiring.
The analyst said shares trade at price to earnings multiples of 25X or higher for fiscal year 2025 and 2026 estimates, "despite no projected revenue growth."
A leadership change could offer a better chance at a turnaround, but could be a long process, Cirello added.
"We view the move as a step in the right direction that can help reinvigorate the brand and improve sentiment on the stock, given that Mr. Hill is very well-respected and knows the business well from his 32-year Nike tenure," Cirello said.
Cirello said there could be "a long road ahead with a lot of potential bumps in the road."
RBC Capital on NKE: Given the recent struggles in share price, the announcement of a new CEO at Nike is a welcome development, Dadhania said in a recent investor note.
"Nike CEO change is unlikely to surprise the market, given investor discontent with the overall management and direction of the business in recent years, as well as increasing competition from newer players and incumbents," Dadhania said.
The analyst said Hill understands Nike's history, Nike's culture and the sportswear market, which could be a winning combination.
"We think this was the icing on the cake that the Nike bulls have been waiting for."
Goldman Sachs on NKE: Roach said in a note Thursday that Hill's background with Nike could be a key strength in helping with the company's turnaround.
"We are encouraged by today's announcement and are pleased that NKE's next CEO has a deep-rooted understanding of NKE culture, storytelling, and marketplace," Roach said.
Hill's comment on looking forward to delivering bold and innovative products caught the attention of the analyst and could be a positive ahead of the Investor Day.
"We look for initial thoughts from Mr. Hill regarding his initial priorities and an articulation of the updated NKE strategy, including channel and marketplace, innovation, demand creation, and opportunities to accelerate momentum in a competitive marketplace."
JPMorgan on NKE: Elliott's expertise and leadership style were credited with winning the CEO job, Boss said.
The analyst highlighted Nike's history with long-tenured managers as part of "the old guard."
"This represents a shift back to a seasoned Nike veteran as CEO with Hill having spent more than 32 years at Nike in various leadership roles, akin to Chairman and former CEO Mark Parker's resume of spending 27 years at Nike prior to his CEO appointment in 2006," Boss said.
Parker helped Nike produce high-single-digit revenue growth and mid-teens earnings per share growth, the analyst added.
NKE Price Action: Nike shares are up 6% to $86.17 on Friday versus a 52-week trading range of $70.75 to $123.39. Nike stock is down 19% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/06/39536852/nike-q4-earnings-highlights-revenue-miss-eps-beat-taking-our-near-term-challenges-head-on">Nike Q4 Earnings Highlights: Revenue Miss, EPS Beat, &#8216;Taking Our Near-Term Challenges Head-On&#8217;</a></li>
</ul>
Photo: JHVEPhoto/Shutterstock.com

Analyst Color

Price Target

Reiteration

Nike CEO Announcement 'Icing On The Cake' For Bulls: 8 Analysts React To Elliot Hill's Ascension

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) investors are bracing for a significant shake-up as the quarterly rebalancing of market index funds coincides with a rare triple witching event, a financial phenomenon that only intensifies market volatility.
<h2 class="wp-block-heading">Busiest Rebalancing In Four Years To Boost Apple </h2>
With $250 billion in stock adjustments underway, the iPhone manufacturer could emerge as one of the biggest beneficiaries. 
A notable shift comes from Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) trimming its stake, increasing the share count used by index providers to determine Apple's weight, pushing the Cupertino, California-based company&#8217;s stock to the top of S&amp;P 500 tracking funds.
<h2 class="wp-block-heading">Apple To Take The Lead Over Microsoft</h2>
Apple&#8217;s market capitalization of $3.48 trillion now surpasses Microsoft Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) $3.26 trillion, positioning the tech titan to be the largest holding in the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>).
As funds rebalance, a hefty $35 billion worth of Apple shares will need to be bought, which could provide significant support to its stock price. This reshuffling may further amplify the bullish momentum Apple has enjoyed year-to-date, with the stock already up over 24%.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40940715/apple-revenue-growth-just-too-slow-for-investors-to-get-excited-about-analyst-highl">Apple Revenue Growth &#8216;Just Too Slow For Investors To Get Excited About&#8217;: Analyst Highlights Advertising As Future Catalyst</a>
<h2 class="wp-block-heading">Bullish Signals All-Around</h2>
Apple&#8217;s stock chart is radiating strength, signaling continued bullish action.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM.png" alt="" class="wp-image-558956" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134327/Screenshot-2024-09-20-at-11.12.34-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
With the stock trading above key moving averages — five, 20 and 50 days — the technical setup strongly favors buyers. The share price of $231.12 sits comfortably above its eight-day SMA of $221.71 and 20-day SMA of $223.84, offering a consistent bullish signal across multiple indicators.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="458" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM.png" alt="" class="wp-image-558957" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/20134329/Screenshot-2024-09-20-at-11.12.51-PM-300x218.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent092024&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The Moving Average Convergence Divergence (MACD) suggests more buying pressure with a positive reading, while the Relative Strength Index (RSI) of 63.00 (and rising) indicates that although Apple is nearing overbought territory, the bullish momentum remains intact.
With the rebalancing aligning with positive technicals, investors are betting that Apple could soar further.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40958207/how-apple-stock-could-gain-from-fridays-s-p-500-rebalancing-what-investors-should-know">How Apple Stock Could Gain From Friday&#8217;s S&amp;P 500 Rebalancing: What Investors Should Know</a></li>
</ul>

Long Ideas

Technicals

Tech

AAPL

MSFT

Apple Vs. Microsoft: Can A $35B Rebalance Amplify Bullish Momentum?

Sony Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) revealed the highly anticipated Silent Hill 2 remake would remain a PlayStation 5 console exclusive for one year, with other platforms not receiving the game until at least<a href="https://www.benzinga.com/general/gaming"> Oct. 8, 2025. </a>
Fans of the psychological horror classic have been eagerly awaiting this remake, developed by Bloober Team, which promises to retain the eerie charm of the 2001 original while introducing several new gameplay elements.
See Also: <a href="https://www.benzinga.com/general/gaming/24/09/40947591/playstation-celebrates-30-years-with-retro-themed-ps5-pro-and-slim-editions">PlayStation Celebrates 30 Years With Retro-Themed PS5 Pro And Slim Editions</a>
<h1 class="wp-block-heading">Exclusive PS5 Features</h1>
The announcement, first <a href="https://www.eurogamer.net/silent-hill-2-remake-will-be-a-ps5-console-exclusive-for-one-year">spotted</a> by Eurogamer in a new PlayStation trailer, confirms the remake will launch on both PC and PS5 on Oct. 8, 2024.
Players on other consoles, such as Xbox Series X&#x7C;S or Nintendo's next-gen console (potentially dubbed the Switch 2), will have to wait a full year for access. 
Sony has also confirmed full support for the PS5's DualSense controller in the Silent Hill 2 remake, taking advantage of its unique features like haptic feedback, adaptive triggers, and a dynamic lightbar.
<h1 class="wp-block-heading">Staying True to the Original with Modern Gameplay Enhancements</h1>
The Silent Hill 2 remake reimagines one of the most beloved psychological horror games of all time. The story follows James Sunderland, who receives a cryptic letter from his deceased wife, Mary, urging him to return to the eerie town of Silent Hill. 
As players guide James through the monster-infested town, they must piece together the unsettling mystery, all while facing a slew of terrifying foes.
Despite the introduction of modern gameplay mechanics, Bloober Team has remained adamant that the game's narrative will remain faithful to the 2001 original. 
However, they estimate players will take around 16 to 18 hours to complete the game, a noticeable increase from the original. This extended playtime is due to the revamped gameplay rather than any changes in the storyline.
Earlier this month, footage of the first 90 minutes of gameplay surfaced online, showcasing just under 10% of the game. 
For those looking to experience Silent Hill 2 with the highest possible fidelity, the game will also be compatible with the upcoming PS5 Pro, launching on Nov. 7, 2024. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40907983/september-playstation-plus-lineup-whats-coming-and-whats-leaving">September PlayStation Plus Lineup: What&#8217;s Coming And What&#8217;s Leaving</a></li>
</ul>
Photo: Courtesy of Bloober Team.

Gaming

General

Sony Group Corporation American Depositary Shares

SONY

Silent Hill 2 Remake Locks In PS5 Exclusivity For One Year

Offerings

BANL

CBL International Says May Offer & Sale From Time To Time In One Or More Offerings By Selling Securityholder Of Up To 2.5M Ordinary Shares

Yesterday, Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) reported first-quarter adjusted earnings per share of $1.75, missing&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40943086/darden-misses-q1-earnings-estimates-partners-with-uber-for-delivery-expansion" rel="noreferrer noopener">the analyst consensus estimate of $1.83.&nbsp;</a>Quarterly sales of $2.76 billion missed the street view of $2.80 billion.
Analysts covering <a target="_blank" href="https://www.benzinga.com/quote/DRI/analyst-ratings" rel="noreferrer noopener">the company provided their takes:</a>
<ul>
<li>KeyBanc Capital Markets analyst Eric Gonzalez reiterated the Overweight rating on the stock, raising the price forecast to $194 from $170.</li>
<li>BMO Capital Markets analyst Andrew Strelzik maintained the Market Perform rating, raising the price forecast to $175 from $165.</li>
<li>Wedbush analyst Nick Setyan reiterated the Outperform rating on Darden Restaurants, raising the price forecast to $200 from $170.</li>
<li>Piper Sandler analyst Brian Mullan reiterated the Neutral rating on the company, raising the price forecast to $177 from $159.</li>
<li>Truist Securities analyst Jake Bartlett maintained the Buy rating, increasing the price forecast to $195 from $185.</li>
</ul>
KeyBanc Capital Markets: The analyst anticipates potential growth from Darden&#8217;s partnership with Uber. Gonzalez also slightly raised the FY25 EPS estimate to $9.48, attributing this adjustment to a modest increase in blended same-store sales growth as Darden focuses more on price point advertising at Olive Garden. Darden will test delivery at approximately 100 Olive Garden locations during the holiday season, with plans to expand to the entire Olive Garden network by the end of FY25. It&#8217;s important to note that delivery menu prices will match those for dine-in and takeout, but customers will incur a $5 delivery fee plus a 5% service charge for this convenience.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/40876180/darden-restaurants-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-mos" rel="noreferrer noopener"> Darden Restaurants Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
BMO Capital Markets: While the analyst expects the company to gain incremental benefits from delivery and views the deal structure positively, they wouldn&#8217;t be surprised if sales growth lags behind competitors due to potential overlap with its existing substantial off-premise business and its absence from the third-party marketplace. Currently, Strelzik forecasts a modest boost to Olive Garden&#8217;s comparable sales in the second half of 2025 and a low-single-digit increase in FY2026.
Wedbush: The analyst projects that DRI will continue to gain market share even in a challenging consumer landscape, suggesting a strong likelihood of achieving its long-term annual return targets. The analyst emphasizes the company&#8217;s on-demand delivery collaboration with Uber, starting with a pilot in 5-6 Olive Garden units. This will expand to approximately 100 units in FQ2 ahead of the holidays, eventually launching at all Olive Garden locations with curbside to-go by the end of FY25. The partnership is set up as a first-party delivery model, and there are no plans to advertise on UberEats.
Piper Sandler: According to the analyst, the Uber partnership will begin with Olive Garden, the company&#8217;s largest brand, accounting for about 45% of revenue and 50% of segment profit in Fiscal Year 2024. Given Olive Garden&#8217;s significance to the company&#8217;s financial model, this could lead to an unexpected boost in Darden&#8217;s adjusted EPS, especially in the following year, prompting a positive reaction in the stock today.
Truist Securities: The analyst is optimistic about the widespread improvement in same-store sales (SSS) across Darden&#8217;s portfolio since July. This, along with more proactive marketing efforts and easier year-over-year comparisons in the second half of FY25, enhances the analyst&#8217;s confidence that the accelerating SSS and market share gains will bolster Darden&#8217;s premium valuation.
Price Action: DRI shares are trading lower by 1.41% to $169.85 at last check Friday.
Photo: Courtesy of Dutchmen Photography via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40957191/this-pepsico-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday" target="_blank" rel="noreferrer noopener">This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

SandRidge Mississippian

News

Latest news for SandRidge Mississippian (OTC:SDTTU) Stock